GAINESVILLE, Fla. – March 8, 2010 -- Exactech Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, today announced its schedule of upcoming investor events.

Exactech will meet with and present to investment financial analysts on March 9, 2010 at the Canaccord Adams Musculoskeletal Conference to be held in New Orleans directly preceding the American Academy of Orthopedic Surgeons (AAOS) Annual Meeting. The investor conference includes companies in orthopaedics, biologics, imaging, robotic surgery and regenerative tissue. Exactech President David Petty will deliver his presentation to the financial community at 11:40 AM, which will also be available via audio webcast at http://www.hawkassociates.com/profile/exac.cfm.

Exactech will then host three days of investor and financial analyst meetings at the company’s technical exhibit showcasing new product offerings and demonstrations for orthopaedic surgeons during the AAOS Annual Meeting in New Orleans March 10-12, 2010.

Key new products and featured demonstrations will include:

• Knee: Introduction of the next generation of Exactech’s flagship knee system, the Optetrak Logic® with an efficient, bone-preserving posterior stabilized technique; Optetrak CR Slope®, an advanced technique and implant system that preserves the posterior cruciate ligament; and Low Profile Instrumentation system with new tibial and patellar offerings.

• Hip: Additions to the Novation® comprehensive hip system including low-demand press fit and cemented stems using a ‘quick-kit’ shared core instruments. Novation Element® was recently added to offer a tapered wedge stem, supported by instruments that enable the direct anterior approach technique.

• Extremity: Equinoxe® Platform Fracture Stem, recently FDA-cleared and the latest addition to the Equinoxe product family of primary and reverse shoulder stems. Compatible with Equinoxe® Reverse components, giving surgeons the intra-operative flexibility to perform a hemi-arthroplasty or reverse total shoulder. Exactech is currently conducting clinical evaluations of the fracture stem, with full launch targeted for the second half of 2010.

• Biologic: Exactech enters the sports medicine market with the introduction of Accelerate® PRP Sport™, which allows clinicians to collect a small amount of the patient’s blood and process it in the office to concentrate the platelets. Once harvested, these concentrated platelets are injected into the injured area. These concentrated platelets contain powerful growth factors that can jumpstart the healing of injured tendons and ligaments by stimulating tissue repair and regeneration.

• Revision: Expansion of InterSpace® pre-formed temporary spacers with gentamicin that maintain joint space and allow for assisted mobility during treatment of two-stage septic revision surgery. New High Release design in hip, knee and shoulder forms features increased porosity and greater surface area allowing greater antimicrobial activity than other treatment options.

• Spine: Improved new HydraLok® Polyaxial Pedicle Screw System for spine reconstruction

Throughout the three day AAOS Technical Exhibit, orthopaedic surgeons and other technical experts will be available to discuss design rationales and clinical outcomes associated with Exactech products.

About the AAOS

Founded in 1933, The American Academy of Orthopaedic Surgeons is the preeminent provider of musculoskeletal education to orthopaedic surgeons and others in the world. Its continuing medical education activities include a world-renowned annual meeting, multiple CME courses held around the country and at the Orthopaedic Learning Center, and various medical and scientific publications and electronic media materials. http://www.aaos.org/education/anmeet/anmeet.asp.

About Exactech

Based in Gainesville, Florida, Exactech develops and markets orthopaedic implant devices, related surgical instruments and biologic materials and services to hospitals and physicians. The company manufactures many of its orthopaedic devices at its Gainesville facility. Exactech’s orthopaedic products are used in the restoration of bones and joints that have deteriorated as a result of injury or diseases such as arthritis. Exactech markets its products in the United States and Australia, in addition to more than 30 markets in Europe, Asia and Latin America. Additional information about Exactech, Inc. can be found at http://www.exac.com. An Exactech investment profile is online at http://www.hawkassociates.com/profile/exac.cfm. To receive e-mail alerts about EXAC, sign up at http://www.hawkassociates.com/about/alert.

This release contains various forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which represent the company’s expectations or beliefs concerning future events of the company’s financial performance. These forward-looking statements are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include the effect of competitive pricing, the company’s dependence on the ability of third party manufacturers to produce components on a basis which is cost-effective to the company, market acceptance of the company’s products and the effects of government regulation. Results actually achieved may differ materially from expected results included in these statements.

*************

Investor Contacts:

Exactech CFO Jody Phillips at 352.377.1140

Hawk Associates 305-451-1888

Julie Marshall or Frank Hawkins

exactech@hawkassociates.com

PDF